Literature DB >> 18947869

John Auer and Auer rods; controversies revisited.

Yataro Yoshida1, Shigeru Oguma, Hitotshi Ohno.   

Abstract

John Auer first described needle or rod-shaped intracytoplasmic inclusion bodies in leukemia cells in 1906. Auer rods can be seen in myeloid neoplasms ranging from acute myeloid leukemias (AML) to myelodysplasia, but not in normal or non-neoplastic reactive states. This article briefly describes John Auer's experience and discusses debates on Auer rods, and criticizes their place in the definition of refractory anemia with excess of blasts-2 (RAEB-2) in the WHO classification of the myelodysplastic syndromes (MDS).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18947869     DOI: 10.1016/j.leukres.2008.09.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-2.

Authors:  Yi Wang; Yaoyao Shen; Jiaqian Qi; Jia Chen; Yang Xu; Feng Chen; Xiao Ma; Miao Miao; Shengli Xue; Huiying Qiu; Xiaowen Tang; Yue Han; Suning Chen; Aining Sun; Yanming Zhang; Depei Wu; Ying Wang
Journal:  Ann Hematol       Date:  2022-03-02       Impact factor: 3.673

2.  Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.

Authors:  Huijun Huang; Tiejun Qin; Zefeng Xu; Zhongxun Shi; Bing Li; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert P Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2019-12-27       Impact factor: 8.615

3.  Auer Rods Are Not Seen in Non-Neoplastic Cells.

Authors:  İrfan Yavaşoğlu; Zahit Bolaman
Journal:  Turk J Haematol       Date:  2016-12-01       Impact factor: 1.831

Review 4.  Lysosomes in Stem Cell Quiescence: A Potential Therapeutic Target in Acute Myeloid Leukemia.

Authors:  Vaibhav Jain; Swaroop Bose; Awadhesh K Arya; Tasleem Arif
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.